Figure 2

Intrasplenic and intrapancreatic injections of adipose tissue-derived mesenchymal stem cells improve peripheral response to glucose in streptozotocin-induced diabetic mice. Glucose tolerance tests (GTTs) were performed in 10-hour fasting mice 65 days after adipose tissue-derived mesenchymal stem cell (ADMSC)/phosphate-buffered saline (PBS) administration. Glucose (1.5 mg/g) was intraperitoneally administered and blood glucose levels (mg/dl) were determined 0, 15, 30, 60, 120 and 180 minutes after administration. (A, C). Responder ADMSC-treated mice (R-ADMSCs) exhibited lower blood glucose levels than control mice (Control-PBS) and nonresponder mice (NR-ADMSCs) during the GTT. WT, wild-type/nondiabetic mice (n = 2). (B, D) Area under the curve (AUC) of glycemia during the GTT was determined for each animal and the average ± standard deviation of each group is shown. Intrasplenic route: Control-PBS, n = 5; R-ADMSCs-treated, n = 7; NR-ADMSCs, n = 3. Intrapancreatic route: Control-PBS, n = 5; R-ADMSCs, n = 5; NR-ADMSCs, n = 7. *P <0.05 (Control-PBS vs. R-ADMSCs), ^# P <0.05 (R-ADMSCs vs. NR-ADMSCs), &P < 0.05 (WT vs. R-ADMSCs, for all evaluated time points).